Vermont 28 Park Ave Suite #1A Williston, VT 05495





Date:					
	PATIENT I		TION	,	
Name:	Phone:		DOB:	SEX:	M 🗆 F 🗆
□NKDA Allergies:				Weight lbs/kg:	
	PHYSICIAN	INFORM	ATION		
Physician Name:		Practice Nam			
Address:		Office Contact Name: Office Contact #:			
Phone: Fax:		Email (for updates):			
	REFERRAI	STATUS			
□New Referral □Referral Renewal □N	Medication/Order Cha	ınge □Ben	efits Verificatio	n Only □Discon	tinuation Order
MEDICATION ORDERS □ gMG who are anti-acetylcholine receptor (ArchR) antibody+ ICD 10: gMG NEW START dosing (adult dosing) □ 900 mg weekly for the first 4 weeks, followed by □ 1,200 mg for the fifth dose 1 week later then □ 1,200 mg every 2 weeks x • Refills* □None □x6 months □x1year □Other: *(if not indicated order will expire one year from date signed		□ atypical Hemolytic Uremic Syndrome (aHUS) ICD 10: aHus NEW START dosing (18 yo and older)* □ 900 mg weekly for the first 4 weeks, followed by □ 1,200 mg for the fifth dose 1 week later then □ 1,200 mg every 2 weeks x • Refills* □None □x6 months □x1year □Other: *(if not indicated order will expire one year from date signed) PT wt and dosing Body WT Introduction Maintenance			
ICD 10:		□ WT	30kg to < 40kg	600mg weekly x 2 doses	900mg at week 3 then 900mg every 2 weeks
PNH BKEMV NEW START dosing (18 yo and older)	□ WT	20kg to < 30kg	600mg weekly x 2 doses	600mg at week 3 then 600mg every 2 weeks	
□ 600 mg weekly for the first 4 weeks, followed by □ 900 mg for the fifth dose 1 week later then □ 900 mg every 2 weeks x • Refills* □None □x6 months □x1year □Other: *(if not indicated order will expire one year from date signed		□ wt	10kg to < 20kg	600mg weekly x 1 doses	300mg at week 2 then 300mg every 2 weeks
		WT	5kg to <10kg	300mg weekly x 1 doses	300mg at week 2 then 300mg every 3 weeks
		***Complete or update vaccination from meningococcal bacteria (for serogroups A,C,W,Y, and B) at least 2 weeks prior to the first dose of BKEMV, unless the risks of delaying therapy with BKEMV outweigh the risk of developing a serious infection.Comply with the most current			
REQUIRED DOCUMENTATION CHECKLI	IST:	Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a			
□ This signed order form by the provider □ Patient demographics AND insurance information		complement inhibitor. See Warning and Precautions (5.1) for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.			
□ Acetylcholine Receptor Antibody Test Results (if Myasthenia Gravis)		WARNINGS AND PRECAUTIONS https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761333s001lbl.pdf			
Documentation of meningococcal vaccines WITH DATES OF ADMINISTRATION OF MEN WITH DATES OF ADMINISTRATION OF MEN IF NOT FULLY VACCINATED PROPHYLACTION	N ABCWY OR				

ORDERING PROVIDER

ORDERING I ROVIDER		
Signature X		Date
Provider	Phone	Provider NPI
·		

□ Is your patient enrolled in the BKEMV REMS program □YES □NO (If no, must be enrolled to start therapy)

□ Is the ordering PROVIDER enrolled in the BKEMV REMS program □YES □NO (If no, must be enrolled to start therapy)